1887

Journal of General Virology header logo

Volume 78, Issue 4

Serological and T-helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls Free

Abstract

In a cross-sectional study we have investigated serological and T-helper (Th) cell responses to human papillomavirus type 16 (HPV-16) L1 in women with HPV-16 related diseases and related them to cervical histology and HPV DNA status. Using a virus-like particle (VLP) based ELISA to detect antibodies to the HPV-16 L1 capsid protein, 45% (33/73) of women with cervical dysplasia, 40% (2/5) of women with cervical cancer, 36% (4/11) of healthy adult female controls and 6% (2/35) of healthy children were found to be seropositive. Amongst women with cervical dysplasia, the highest levels of seropositivity were found in those who were HPV-16 DNA positive (60%, 15/25) or positive for any of the ‘high-risk’ HPV types, 16/18/33 (58%, 18/31), when compared with those with HPVtype ‘X’ (25%, 5/20) or with healthy children (6%, 2/35; < 0·05 for all comparisons). There was a trend for women with cervical dysplasia to show an increased level of seropositivity with increasing grade of lesion. There was no direct correlation found between seropositivityand Th cell responses in all groups studied. However, a combined analysis of each individual’s Th and B cell responses suggests that a Th1 pattern of response is predominant amongst healthy adult controls (80% of responders) but reduced in women with cervical dysplasia (55% of responders). A trend towards a decrease in Th1 type responses was also noted with increasing grade of dysplastic lesion. These findings provide further evidence for the importance of the Th response in the control of genital HPV infections.

  • Published Online:
© Society for General Microbiology Ltd 1997
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-78-4-917
1997-04-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/78/4/9129666.html?itemId=/content/journal/jgv/10.1099/0022-1317-78-4-917&mimeType=html&fmt=ahah

References

  1. Coleman N., Birley H. D., Renton A. M., Hanna N. F., Ryait B. K., Byrne M., Taylor-Robinson D., Stanley M. A. 1994; Immunological events in regressing genital warts. American Journal of Clinical Pathology 102:768–774
     [Google Scholar]
  2. Dillner J., Wiklund F., Lenner P., Eklund C., Fredriksson-Shanazarian V., Schiller J. T., Hibma M., Hallmans G., Stendahl U. 1995; Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. International Journal of Cancer 60:377–382
     [Google Scholar]
  3. Galloway D. A. 1992; Serological assays for the detection of HPV antibodies. In The Epidemiology of Human Papillomavirus and Cervical Cancer pp. 147–161 Munoz N., Bosch F. X., Shah K. V., Meheus A. Edited by Lyon, France: IARC Science Publications;
     [Google Scholar]
  4. Ho G. Y., Burk R. D., Klein S., Kadish A. S., Chang C. J., Palan P., Basu J., Tachezy R., Lewis R., Romney S. 1995; Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. Journal of the National Cancer Institute 87:1365–1371
     [Google Scholar]
  5. Kirnbauer R., Hubbert N. L., Wheeler C. M., Becker T. B., Lowy D. R., Schiller J. T. 1994; A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. Journal ofthe National Cancer Institute 86:494–499
     [Google Scholar]
  6. Koutsky L. A., Holmes K. K., Critchlow C. W., Stevens C. E., Paavonen J., Beckmann A. M., DeRouen T. A., Galloway D. A., Vernon D., Kiviat N. B. 1992; A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. New England Journal of Medicine 327:1272–1278
     [Google Scholar]
  7. Lorincz A. T., Reid R., Jensen A. B., Greenberg M. D., Lancaster M. W., Kurman R. J. 1992; Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstetrics and Gynecology 79:328–337
     [Google Scholar]
  8. Nonnenmacher B., Hubbert N. L., Kirnbauer R., Shah K. V., Munoz N. , Bosch F. X., de Sanjose S., Viscidi R., Lowy D. R., Schiller J. T. 1995; Serologic response to human papillomavirus type 16 virus-like particles in HPV16 DNA positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. Journal of Infectious Diseases 172:19–24
     [Google Scholar]
  9. Resnick R. M., Cornelissen M. T., Wright D. K., Eichinger G. H., Fox H. S., ter Schegget J., Manos M. M. 1990; Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. Journal of the National Cancer Institute 82:1477–1484
     [Google Scholar]
  10. Rose R. C., Bonnez W., Reichman R. C., Garcea R. L. 1993; Expression of human papillomavirus type 11 L1 protein in insect cells : in vivo and in vitro assembly of virus-like particles. Journal of Virology 67:1936–1944
     [Google Scholar]
  11. Rose R. C., Bonnez W., DaRin C., McCance D. J., Reichman R. C. 1994a; Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. Journal of General Virology 75:2445–2449
     [Google Scholar]
  12. Rose R. C., Reichman R. C., Bonnez W. 1994b; Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. Journal of General Virology 75:2075–2079
     [Google Scholar]
  13. Shepherd P. S., Rowe A. J., Cridland J. C., Coletart T., Wilson P., Luxton J. C. 1996; Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia. Journal of General Virology 77:593–602
     [Google Scholar]
  14. Snijders P. J., van den Brule A., Schrijnemakers H., Snow G., Meijer C., Walboomers A. 1990; The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. Journal of General Virology 71:173–181
     [Google Scholar]
  15. van den Brule A. J., Snijders P. J., Raaphorst P. M., Schrijnemakers H. F., Delius H., Gissmann L., Meijer C. J., Walboomers J. M. 1992; General primer polymerase chain reaction in combination with sequence analysis for identification of potentially novel human papillomavirus genotypes in cervical lesions. Journal of Clinical Microbiology 30:1716
     [Google Scholar]
  16. Wikstrom A., van Doornum G. J., Quint W. G., Schiller J. T., Dillner J. 1995; Identification of human papillomavirus seroconversions. Journal of General Virology 76:529–539
     [Google Scholar]
  17. Wright D., Manos M. 1990; Sample preparation from paraffin- embedded tissues. In PCR Protocols: A Guide to Methods and Applications pp. 153–158 Innis M. A., Gelfand D. H., Sninsky J. J., White T. J. Edited by San Diego: Academic Press;
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-78-4-917
Loading
Serological and T-helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls
J. Gen. Virol. 78, 917 (1997); https://doi.org/10.1099/0022-1317-78-4-917
/content/journal/jgv/10.1099/0022-1317-78-4-917
/content/journal/jgv/10.1099/0022-1317-78-4-917
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error